semaglutide anaesthesia Obesity and – Anaesthesia News Semaglutide for obesity – how

Michael Calore: Yeah, that's awesome

Clinical studies and our extensive patient experience at Internal Medicine and Family Practice show that the vast majority of patients experience a substantial decrease in hunger and achieve meaningful weight loss

Tirzepatide initiation begins at 2.5mg weekly, increasing in 2.5mg increments every four weeks to a maintenance dose of 515mg 6

Additional considerations for optimizing treatment include moderating alcohol consumption due to pancreatitis risk and managing constipation through adequate fiber, fluids, and physical activity

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists has become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries